Meeting
2017 ASCO Annual Meeting
Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced/metastatic renal cell carcinoma (mRCC).
Authors
Brian I. Rini
Cleveland Clinic, Cleveland, OH
Brian I. Rini , Thomas Powles , Mei Chen , Markus Puhlmann , Michael B. Atkins
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT02853331
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS4597)
DOI
10.1200/JCO.2017.35.15_suppl.TPS4597
Abstract #
TPS4597
Poster Bd #
271b
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.
First Author: Robert J. Motzer
Poster
2017 ASCO Annual Meeting
A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC).
First Author: Robert J. Motzer
Poster
2023 ASCO Quality Care Symposium
Uptake and efficacy of immuno-oncology combinations in metastatic renal cell carcinoma in the United States: Evidence from the ASCO CancerLinQ Discovery database.
First Author: Joseph Vento
Poster
2023 ASCO Genitourinary Cancers Symposium
Safety and tolerability of pembrolizumab/axitinib combination in metastatic renal cell carcinoma (mRCC): A multicentric prospective analysis (ProPAXI study).
First Author: Annalisa Guida